Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 14259-46-2
2. Isonaringin
3. Isonaringenin
4. Naringenin-7-o-rutinoside
5. Naringenin 7-o-rutinoside
6. (2s)-narirutin
7. Chebi:28705
8. 06m5eat0yc
9. (2s)-5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-3,4-dihydro-2h-chromen-7-yl 6-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranoside
10. (s)-5-hydroxy-2-(4-hydroxyphenyl)-7-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-((((2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)methyl)tetrahydro-2h-pyran-2-yl)oxy)chroman-4-one
11. Mfcd00017316
12. Naringenin 7-beta-rutinoside
13. Fema No. 2769
14. Brovincaminefumarte
15. Einecs 238-138-0
16. Naringen
17. Naringin Extract (citrus Paradisi Macf.)
18. Narirutin [inci]
19. Unii-06m5eat0yc
20. Isonaringin [usp-rs]
21. Schembl669946
22. Chembl446246
23. Narirutin, >=98% (hplc)
24. Dtxsid30931535
25. Hy-n0804
26. Zinc8234300
27. Bdbm50249471
28. S9242
29. Naringenin 7.beta.-rutinoside
30. Akos030530132
31. Ccg-270129
32. (2s)-5-hydroxy-2-(4-hydroxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one
33. As-75180
34. Cs-0009810
35. N1696
36. C09793
37. 259n462
38. Flavanone, 4',5,7-trihydroxy-, 7-beta-rutinoside
39. Q-100159
40. Q13569061
41. Flavanone, 4',5,7-trihydroxy-, 7.beta.-rutinoside
42. (2s)-5-hydroxy-2-(4-hydroxyphenyl)-7-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-3,4-dihydro-2h-1-benzopyran-4-one
43. (2s)-7-((6-o-(6-deoxy-.alpha.-l-mannopyranosyl)-.beta.-d-glucopyranosyl)oxy)-2,3-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-4h-1-benzopyran-4-one
44. (s)-5-hydroxy-2-(4-hydroxyphenyl)-7-((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(((2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yloxy)methyl)tetrahydro-2h-pyran-2-yloxy)chroman-4-one
45. (s)-7-((6-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosyl)oxy)-2,3-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-4h-1-benzopyran-4-one
46. 4h-1-benzopyran-4-one, 7-((6-o-(6-deoxy-.alpha.-l-mannopyranosyl)-.beta.-d-glucopyranosyl)oxy)-2,3-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-, (2s)-
47. 4h-1-benzopyran-4-one, 7-((6-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranoxyl)oxy)-2,3-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-, (s)-
48. 4h-1-benzopyran-4-one,7-[[6-o-(6-deoxy-a-l-mannopyranosyl)-b-d-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-, (2s)-
| Molecular Weight | 580.5 g/mol |
|---|---|
| Molecular Formula | C27H32O14 |
| XLogP3 | -1.1 |
| Hydrogen Bond Donor Count | 8 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 6 |
| Exact Mass | 580.17920569 g/mol |
| Monoisotopic Mass | 580.17920569 g/mol |
| Topological Polar Surface Area | 225 Ų |
| Heavy Atom Count | 41 |
| Formal Charge | 0 |
| Complexity | 884 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 11 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Narirutin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Narirutin, including repackagers and relabelers. The FDA regulates Narirutin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Narirutin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Narirutin supplier is an individual or a company that provides Narirutin active pharmaceutical ingredient (API) or Narirutin finished formulations upon request. The Narirutin suppliers may include Narirutin API manufacturers, exporters, distributors and traders.
Narirutin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Narirutin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Narirutin GMP manufacturer or Narirutin GMP API supplier for your needs.
A Narirutin CoA (Certificate of Analysis) is a formal document that attests to Narirutin's compliance with Narirutin specifications and serves as a tool for batch-level quality control.
Narirutin CoA mostly includes findings from lab analyses of a specific batch. For each Narirutin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Narirutin may be tested according to a variety of international standards, such as European Pharmacopoeia (Narirutin EP), Narirutin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Narirutin USP).
LOOKING FOR A SUPPLIER?
